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Abstract: BACKGROUND: The introduction of multiparametric magnetic resonance imaging
(mpMRI) has improved the diagnosis of suspected prostate cancer, accurately risk-stratifying men
before a biopsy. However, pre-biopsy mpMRI represents a significant deviation from the traditional
approach of prostate specific antigen testing with subsequent systematic transrectal ultrasound-guided
prostate biopsy and we have not yet explored the views of men who experience this new pathway.
The purpose of the PACT study (PAtient views and aCceptance of mulTiparametric MRI) is to explore
men’s perceptions of mpMRI. METHODS: PACT will be conducted at teaching hospitals in which
mpMRI is central to the prostate cancer diagnostic pathway using a two-phase, mixed-methods,
quantitative and qualitative approach. In phase I, men referred with suspected prostate cancer will
complete detailed surveys to explore their views on the mpMRI-directed pathway compared to the
traditional pathway and on what constitutes ‘significant’ prostate cancer. In phase II, these themes
will be expanded upon with in-depth, semi-structured interviews. Qualitative data will be transcribed
and thematically analysed, and quantitative questionnaire responses will be analysed statistically.
DISCUSSION: PACT will provide the first detailed insight into patient perceptions on the use and
acceptability of mpMRI. Furthermore, results from PACT will help contribute to the resolution of
outstanding controversies that surround this technology.
Keywords: diagnostic pathway; multiparametric MRI; patient views; prostate cancer; risk
stratification
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1. Introduction
1.1. Multiparametric Prostate MRI
The introduction of multiparametric magnetic resonance imaging (mpMRI) has enhanced the
risk stratification for men at risk of prostate cancer [1]. Precision imaging, delivered through mpMRI,
has addressed longstanding drawbacks of the traditional approach to prostate cancer diagnosis and
is now integrated into the 2019 National Institute for Health and Care Excellence (NICE) Guidelines
for men with suspected prostate cancer [2,3]. Classically, men with suspected prostate cancer would
undergo serum prostate specific antigen (PSA) testing in the community, followed by systematic
(random) transrectal ultrasound-guided (TRUS) biopsies. This approach carries risks, including the
over-detection of insignificant cancer, over-treatment of insignificant cancer and under-detection of
significant cancer [4], largely because traditional TRUS-guided biopsy is blind to cancer location [5].
Moreover, combining PSA testing with systematic TRUS-guided biopsy has been shown to fail at
identifying men at risk of premature prostate cancer-related death [6]. In contrast, mpMRI has excellent
diagnostic accuracy in the detection of clinically significant prostate cancer and the use of mpMRI
before prostate biopsy enables more accurate pre-biopsy risk-stratification and lesion identification [1].
Pre-biopsy triage with mpMRI has now demonstrated that a proportion of men could safely avoid
TRUS-guided biopsy and its associated side-effects, including pain, bleeding, infection, sepsis and
anxiety (which is distinct from the general distress of a cancer diagnosis) [7,8].
1.2. Patient Perceptions of Prostate mpMRI
The views of clinicians (primarily urologists, radiologists and oncologists) have generally been
favourable toward mpMRI [9–11]. However, we have not yet explored the views of the men who
experience this novel pathway, in depth. In one study, Ullrich and colleagues surveyed a mixed group
of men (with and without prostate cancer) on their views on prostate mpMRI in Germany [12]. They
found that the majority (68%) considered mpMRI to be a useful method to obtain a prostate cancer
diagnosis. However, they also found that only a minority (29%) had personally experienced mpMRI
and that few had any knowledge of the role that mpMRI might play in any new risk-stratification
process. Whilst this work helps in understanding the views that men may have about mpMRI, it
does not give enough detail to shape the way that this technology is both explained and delivered in
practice [13,14]. A rigorous exploration of the perceptions that men have about the accuracy and utility
of mpMRI would help to contribute to the resolution of many of the uncertainties and questions that
still surround its use.
1.3. Uncertainties of Prostate mpMRI
A small proportion (10–20%) of significant prostate cancers go undetected by mpMRI [1]; however,
the true sensitivity and specificity varies due to wide intra-reader and inter-reader variability. To
date, it is unknown whether men with suspected prostate cancer are willing to balance the benefits
and drawbacks of the new mpMRI-directed diagnostic pathway (in which men with non-suspicious
mpMRI may forgo biopsy) as compared to the traditional systematic TRUS-guided biopsy approach.
The nature and acceptability (to clinicians and patients) of prostate cancer that is undetectable
by mpMRI is fundamentally important due to the ramifications it has on how we manage negative
pre-biopsy mpMRI in which no significant cancer is visible (mpMRI scores 1–2). This also affects
prostate biopsy strategies in which we must decide whether to only biopsy visible mpMRI lesions,
or whether the rest of the non-suspicious prostate should be sampled simultaneously. Eliciting and
understanding the opinions that patients have on these important issues will help influence future
clinical decision making.
Here is a summary of the key outstanding uncertainties and questions surrounding mpMRI:
• Acceptance of the diagnostic accuracy of mpMRI
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Many clinicians consider a false negative rate of 10–20% for mpMRI to be excessive, despite
traditional systematic TRUS-guided biopsy having a sensitivity of 48% for the detection of significant
cancer [1]. At present, the level of patient acceptance of the diagnostic performance of these two
approaches is unknown. If patients are willing to accept the level of risk of false negative mpMRI, this
would provide support to the mpMRI-directed diagnostic pathway.
• Agreement to forgo biopsy when the mpMRI is negative
At present, centres that have embraced mpMRI often avoid a biopsy when there is no visible
lesion (i.e., mpMRI scores 1–2). However, this approach is criticised by some, as it carries the risk of
missing a small proportion of mpMRI-invisible significant prostate cancers. Establishing whether men
agree with this mpMRI-directed strategy would help to justify the avoidance of biopsies in cases of
non-suspicious pre-biopsy mpMRI.
• Opinions on lesion-only targeting
An mpMRI-targeted biopsy detects more clinically significant prostate cancer than a traditional
systematic TRUS-guided biopsy [2]. However, many urologists still perform systematic biopsies in
addition to targeted biopsies, based on concerns regarding mpMRI-invisible disease. By exploring
patient perceptions regarding biopsy strategy, we may clarify whether men are supportive of lesion-only
targeting or whether they desire to have their entire prostate sampled, despite the higher risks of the
detection of insignificant disease and biopsy-related side-effects.
• Perceptions of what constitutes ‘significant prostate cancer’
The definition of clinically significant prostate cancer varies, but conventionally relies upon
disease volume and pathological grade, as these are believed to be the strongest determinants of
clinical outcome. However, the true definition of significance has yet to be established. It would be
valuable to explore which aspects of prostate cancer are most significant to men, as their views would
enrich this debate and help to inform diagnostic and treatment decisions, expanding beyond a purely
histopathological definition.
The PACT study (PAtient views and aCceptance of mulTiparametric MRI) aims to explore men’s
views on the role that mpMRI could play and its level of diagnostic acceptability, with a systematic
two-phase, mixed quantitative and qualitative approach. The results from this study will constitute
the first dedicated evidence to address this question.
2. Experimental Design
2.1. Background
The PACT study is a prospective, observational, multi-centre, mixed-methods cohort study that
will include all patients referred with suspected prostate cancer. Patients will be recruited from
prostate cancer assessment clinics that are embedded within the current diagnostic pathway (Figure 1).
Using data from a pilot study at the same hospitals and using an appropriately powered sample size
calculation, we estimate that approximately 122 patients will be needed for phase I (questionnaire
study), which should take approximately six to eight months to recruit (Figure 2).
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Mixed methods will be used to determine patient views on the identified topics surrounding
prostate cancer and mpMRI (Figure 3). In phase I, patients will complete detailed surveys (adapted
from previously validated questionnaires) containing both quantitative and qualitative questions on
the accuracy and use of mpMRI. In phase II, a subset of patients will be recalled to undergo in-depth,
semi-structured interviews to explore these topics in more detail.
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To ensure that the study was reported to a high quality, the Standards for Reporting Qualitative
Research (SRQR) was used to design the qualitative component of this study [15]. The SRQR consists of
21 items to improve the transparency of all aspects of qualitative research by providing clear standards
for reporting qualitative research.
2 Research Question
How do men perceive the risks and benefits of mpMRI during the ia nosti xper ence for
suspected prostate cancer?
2.3. Aims
1. Examine the views of men on the mpMRI diagnostic pathway, including its acceptability and
associated risks, as compared to the traditional approach of random TRUS-guided biopsy.
2. Explore the opinions of men on how clinically significant prostate cancer is currently defined.
.4. Objectives
1. Ascertain the level of acceptability of the mpMRI pathway to men referred with suspected
prostate cancer.
2. Inv stigate the extent to which men with suspecte pr state cancer are willing to tolerate the
cu rent false negative rate associated with mpMRI.
3. Describe the factors that may affect whether patients are willing to accept the drawbacks of the
modern mpMRI pathway, over those of the traditional systematic TRUS-guided biopsy approach.
4. Explore men’s perceptions of different prostate biopsy strategies.
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5. Elucidate men’s views on what constitutes clinically significant prostate cancer, describing this
from a patient perspective.
6. Identify potential areas for the development of patient education and support materials, in light
of these findings.
3. Procedure
3.1. Phase I: Questionnaire Study
3.1.1. Inclusion Criteria
1. Adult male patients (over 18-years-old).
2. Referred with suspected prostate cancer.
3. Undergone prostate mpMRI.
4. Informed consent given to complete questionnaire.
3.1.2. Exclusion Criteria
1. Unable to read, write or understand English.
2. Previous diagnosis of prostate cancer.
3.1.3. Recruitment
All eligible patients who are referred to the prostate cancer assessment clinic, with suspected
prostate cancer, will be invited to be included in the study, provided that they do not have a prior
diagnosis of prostate cancer and have sufficient English language skills. All patients will be invited to
be involved in the study, regardless of their MRI status. The purpose of the study will be explained to
them, along with the proposed data collection methods. Any questions will be answered in detail.
Patients who have had previous investigation (for example, a previous TRUS-biopsy) will not be
excluded from the study, as this will enable these patients to compare their experience of the new
diagnostic pathway with their experiences of the traditional approach. The target for recruitment in
phase I is n = 122, as specified by our sample size calculation, based upon similar patient engagement
research in prostate cancer [16]. The number of patients in each sub-group (for example, by age or
ethnicity) will be determined by availability. The sample size was calculated using a standardised
equation for the comparison of means:
n = [(Zα/2 + Zβ)(Zα/2 + Zβ) × (2 × (SD)(SD))]/(µ1 − µ2)(µ1 − µ2) [17]
Previous similar study data: Kazer et al. (2013) [16]
Where: µ1 − µ2 = 6.5; standard deviation (SD) = 12.8; Zα/2 = 1.96; Zβ = 0.84
n = [(1.96 + 0.84)(1.96 + 0.84) × (2 × (12.8 × 12.8))]/(6.5 × 6.5)
n = 61 (if study divided into two arms)
So, n = 122 (61 × 2)
3.1.4. Data Collection
Once informed, willing patients will sign phase I consent forms (Supplementary Material Figure S1)
and be given copies of the patient information sheet (Supplementary Material Figure S2) and study
questionnaire (Supplementary Material Figure S3). Having read and understood the accompanying
information sheets, patients will complete and return questionnaires before leaving the clinic. The study
questionnaire consists of a modified version of a validated questionnaire previously designed to elicit
patient perceptions of cardiac MRI (permission from the original questionnaire authors has been sought
and approved) [18]. Large fonts and clear English will be used to accommodate the full range of included
patients, with varying eyesight levels, educational attainment and socioeconomic backgrounds.
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3.2. Phase II: Interview Study
3.2.1. Inclusion Criteria
1. Adult male patients (over 18-years-old).
2. Referred with suspected prostate cancer.
3. Undergone prostate mpMRI.
4. Successful completion of the questionnaire in phase I, with informed consent given to be
interviewed in phase II.
3.2.2. Exclusion Criteria
1. Unable speak or understand English.
2. Previous diagnosis of prostate cancer.
3. No contact details given during questionnaire completion.
3.2.3. Recruitment
All men included in phase I will be offered the opportunity to return to phase II to undergo
semi-structured interviews to explore issues of relevance, in greater depth. To incentivise men
to undergo study phase II, interviews will be conducted at the local hospital for each patient (to
minimise disruption with travel and venue unfamiliarity) and patients will be fully informed about the
importance of their involvement in helping to potentially shape the future of the diagnostic approaches
for suspected prostate cancer. To further increase patient engagement, men will be encouraged to
personally review their interview transcripts and any related research materials (for example, journal
articles) that will be produced as a result of their involvement.
A target of 20 men will be recruited for the interview phase. This is based upon standard
practice in qualitative research and will provide a balance of gaining a sufficient breadth and depth
of responses [19]. In order to obtain a rich and diverse qualitative dataset, patients recruited to the
interview phase will be drawn from varied ethnic, educational, socioeconomic and occupational
backgrounds, and will have undergone a range of diagnostic experiences (for example, there will be
a mixture of biopsy-naïve and biopsy-experienced patients) which will enable a more meaningful
comparison of viewpoints.
3.2.4. Data Collection
Interviews will be semi-structured using pre-determined topic guides (Table 1) and are expected
to last between 20 and 30 minutes. After patients have had the interview process explained to them,
and have been consented (Supplementary Material Figure S4), the interviews will be recorded using an
encrypted Dictaphone (Olympus WS-853) and performed in a quiet, pre-booked room on the respective
hospital site. The semi-structured interviews will contain five different themes, as shown in Table 1.
The questions will aim to explore men’s perceptions of prostate mpMRI, prostate biopsy techniques
and definitions of clinically significant disease. They will be open-ended in nature, encouraging a
conversational interview style, in which responses can be expanded upon whenever possible.
Methods Protoc. 2020, 3, 26 8 of 11
Table 1. Themes (topic schedule) to be explored during the interview study.
Background Pathway Comparison Biopsy Strategy Cancer Significance Education
We have begun







would normally have prostate
samples taken through the
back-passage, without an MRI
being performed – this
approach could miss up to
50% of important cancers.
Today, MRI scans are more
readily available and can help
us to detect around 80–90% of
important tumours (if the MRI
is performed before samples
are taken).
When we take a prostate
sample, we can choose to
sample only cancers that







however, this does risk
missing cancers
elsewhere in the prostate.
Alternatively, we can
choose to sample the
“whole prostate” (in
addition to sampling the
‘target’) but this has a










than others and can
spread around the body –
these generally benefit
from treatment. Others
are “less aggressive” and
do not spread or cause
harm – these generally
do not benefit from
treatment and treating
these cancers may cause
more harm than the
cancers themselves.






Can you tell me
what experience
















Would you like to
clarify these issues
before proceeding?
Any new approach has
drawbacks and benefits and
the new MRI approach can
miss 10–20% of prostate
cancers – what do you think of
this? How far does this risk
worry you?
With this in mind, how do you
feel about not taking tissue
samples at all when the MRI
scan appears to be “normal”
or shows “no cancer”?
Can you tell me how you feel
about this compared to the
traditional approach?
When comparing these two
approaches (using MRI or not)
which do you think is more
appealing? And, why?
From your point of view, are
there any aspects of either of
these approaches that would
especially concern you?
Given your own experience to
date, can you think of any
changes or improvements to
these two pathway options
that you would like to see
being made?
Can you tell me, what
experience you have had,
if any, of prostate biopsy?
Do you have any
thoughts on which of the
two major types of
biopsy do you think that
you would prefer? And,
why is this?
If you had an MRI scan
that showed possible
prostate cancer, would
you wish to have:
- Only a “target biopsy”
(in which around 3–5
samples taken from the
suspicious area shown
on the MRI scan)?
- Or, would you rather
have a “targeted and
systematic biopsy” (in
which approximately 12
other samples are also
taken from the rest of the
prostate at the same
time)? And why would
you feel this way?
As a related question,
what proportion of
important cancers would
you be willing to miss?
If you were diagnosed
with prostate cancer,
which aspect of the
cancer would be most
important to you?
Would you be more
concerned about the
effect on your quality of
life (e.g., developing
unpleasant symptoms,
such as problems with
urination) or your life
expectancy (how long
you might live for)? And,
why might you feel this
way?
If you had prostate
cancer, do you think you
would you like to know
about the potential
danger posed by your
cancer? In what way
could we best provide
such information to you?
Do you think you would
want to know about
every single cancer that
is present in your
prostate (even “less
aggressive” cancers) or
do you think you would
only want to know only
about “more aggressive”
cancers? Why would
you feel this way?
What format is
normally best for




aspects of this topic





lessons for us about
your diagnostic
experience to date?
MRI magnetic resonance imaging.
3.3. Data Analysis
3.3.1. Quantitative Analysis
Both the questionnaire and interview phases will contribute to the exploration of patient views
on prostate mpMRI. The questionnaire phase will precede the interview phase and findings from
the questionnaire will be used to inform and evolve the focus of the interview process. Once the
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minimum number of patients have completed the quantitative aspects of the questionnaire study (the
number required to meet our sample size; n = 122), informative statistical analysis will be possible.
GraphPad Prism 8 (Graph-Pad Software, Inc., La Jolla, CA, USA) will be used for all statistical analyses
of quantitative data and the generation of graphical representations of results. The level of statistical
significance will be defined as p < 0.05.
Quantitative data from the outcome measures listed above will be analysed using the appropriate
two-tailed statistical tests to assess for statistically significant differences in groups. All questionnaire
responses will be converted to ordinal (Likert) values (e.g., 1–5), and the responses will be catalogued
in an anonymised master database. Initially, all responses will be analysed with descriptive statistics.
Ordinal values will be analysed with a t-test or the Mann-Whitney U test, depending upon the data
distribution. When statistically appropriate, multivariate analysis will be undertaken. When possible,
analysis will be stratified by key demographic characteristics of interest (for example, age, ethnicity,
medical history and diagnostic experience) to assess for differences in these sub-groups.
3.3.2. Qualitative Analysis
Due to the rich generation of data from the interview study, a smaller sample size (n = 20) will
enable meaningful, qualitative analysis. Audio recordings of the semi-structured interviews will be
transcribed verbatim by an independent scribe and NVivo 12 (QSR International Pty Ltd., Doncaster,
South Yorkshire, UK) will be used for all analyses. Qualitative data will be analysed using thematic
analysis which is “a method for systematically identifying, organising and offering insights into
patterns of meaning (themes) across a dataset” [19].
This process consists of six key steps:
• Step 1: Transcripts will be read whilst re-listening to audio recordings to check accuracy and build
dataset familiarity.
• Step 2: Transcripts will be coded to identify aspects of the data relevant to research objectives.
• Step 3: Codes will be collated into themes.
• Step 4: Themes will be reviewed with the broader research team to ensure code consistency within
themes and to avoid overlap between themes.
• Step 5: A thematic map will be developed by refining themes and analysing their relationships.
• Step 6: The qualitative results will be collated and published using the words of participants to
illustrate areas of agreement, as well as divergences of views.
4. Discussion
In this paper, we describe the methodological design of the PACT study and how quantitative
and qualitative data will be synthesised in a two-phase, mixed-methods approach. To our knowledge,
the PACT study is the first detailed mixed-methods project to explore patient perceptions of the use of
mpMRI for the diagnosis of prostate cancer.
This mixed-methods study centres on the quantitative and qualitative assessment of men’s views
on the benefits and drawbacks of the new diagnostic pathway for prostate cancer as directed by mpMRI,
compared to the traditional systematic TRUS-guided biopsy pathway. It explores the perceptions that
men have regarding the differing approaches to targeted prostate biopsies and their views on what the
definition of truly significant prostate cancer is, as these are all key controversial areas in the field of
prostate cancer diagnostics.
The findings of the PACT study will help clinicians and researchers to understand the views
and potential concerns that men may have around the recent changes to the diagnostic pathway for
suspected prostate cancer. This information will provide valuable patient-centred opinions on some
of the uncertainty and controversial areas that still surround prostate mpMRI. From this, we can
then direct future developments in prostate cancer diagnostic research and the generation of patient
information and education materials, focused on the key areas highlighted in this study.
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